CAMBRIDGE -
The abstracts span Takeda's extensive hematology portfolio and research and development (R&D) pipeline, featuring data on multiple products and investigational candidates, supporting Takeda's commitment to helping healthcare professionals improve the way they treat patients as well as delivering innovative solutions for the future.
'At Takeda, we are advancing a promising pipeline of potentially transformative molecules for multiple rare and life-threatening hematological disorders, while also expanding the body of evidence to support our current portfolio of treatments for people living with rare bleeding disorders,' said
Highlights of data to be presented during ASH include: ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] data in previously untreated patients with severe hemophilia A
Data from the first prospective study evaluating the safety, immunogenicity, and efficacy of ADYNOVATE in previously untreated patients (PUPs), including those younger than six years old, with severe hemophilia A will be presented [Abstract #3184].1
Analysis of joint health from the PROPEL study
Takeda will present post-hoc data from a randomized clinical trial in severe hemophilia A patients on FVIII prophylaxis -the PROPEL study. Six different biomarkers of joint health were measured in 98 patients before and after prophylactic treatment with ADYNOVATE [Abstract #2102].2
This novel biomarker data is the first in a randomized clinical trial to understand the importance of prophylaxis for joint health in patients with hemophilia A, as well as the first study examining longitudinal biomarker levels in a prospective randomized study of severe hemophilia A patients undergoing FVIII prophylaxis at two trough levels (1-3% and 8-12%) to examine the correlation between clinical outcomes and surrogate markers. The results also showed improvement in specific biomarker levels from baseline to study completion [Abstract #2102].2
A cost analysis of prophylaxis with factor VIII replacement and emicizumab in real-world settings
Real-world evidence (RWE) allows healthcare professionals to better understand how medications work in routine clinical practice, potentially advancing patient-centric treatment, particularly in hematological disorders. Takeda is presenting real-world data extracted from the IQVIA PharMetrics Plus database (2015-2020), a longitudinal
'This real-world study helps to illuminate important therapeutic and cost impacts of different treatment options for patients with hemophilia A,' commented study author,
Design of studies further exploring the therapeutic potential of recombinant ADAMTS13 replacement (TAK-755) in cTTP and sickle cell disease (SCD)
Takeda is continuing to assess the potential of TAK-755, a recombinant ADAMTS13 replacement therapy, in patients with severe cTTP, an ultra-rare and potentially life-threatening ADAMTS13 deficiency driven thrombotic disorder.4 The design of a phase 3b open-label continuation study that aims to evaluate the long-term safety and efficacy of TAK-755 for prophylactic and on-demand treatment of severe cTTP will be made available in the ASH program [accepted for online publication only].4
Takeda will also present the design of the first phase 1 study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant ADAMTS13 (TAK-755) in patients with SCD [Abstract #3118].5
rADAMTS13 (TAK-755), is an investigational compound that has not been approved for use by
The Takeda Hematology team is proud to, once again, have a significant presence at ASH along with Takeda Oncology.
About Hemophilia
Hemophilia is a chronic disease that causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood.6 Hemophilia A is more common than hemophilia B; in 2018, hemophilia A affects about 173,711 people, whereas hemophilia B affects about 34,289 people worldwide.7
People with hemophilia, working closely with their healthcare professionals, can live healthy lives with proper care and adequate treatment.8 Treatment regimens typically include on-demand and/or regular prophylactic infusions of factor replacement therapy to control or prevent the risk of bleeding.9
About Takeda Hematology
Takeda is a leader in bleeding disorders with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years driving innovation for patients10 and a broad portfolio of 11 products across multiple bleeding disorders. Our experience as a leader in hematology means we are well prepared to meet today's needs as we pursue future developments in the care of blood disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.
About
Contact:
Tel: +1 774-276-7448
Email: David.Murdoch@takeda.com
Important Notice
For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could' 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in
(C) 2021 Electronic News Publishing, source